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Abstract
The working group “Analyses in Biological Materials” of the Permanent Senate
Commission for the Investigation of Health Hazards of Chemical Compounds in the
Work Area developed and verified the presented biomonitoring method.
This analytical method allows the selective detection of the flame retardant
1,2,5,6,9,10-hexabromocyclododecane (HCBDD) in plasma, with α‑HBCDD,
β‑HBCDD and γ -HBCDD being the three main stereoisomers of technical
HBCDD. The analytes are extracted from plasma after adding the corresponding
13C‑labelled internal standards. After precipitation of the plasma proteins and
solid phase extraction using a Florisil® cartridge, the analytes are separated from
accompanying components by liquid chromatography and analysed using tandem
mass spectrometry. Calibration standards are prepared in plasma and processed in
the same way as the samples to be analysed.
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1 Characteristics of the method
Matrix Plasma
Analytical principle LC-MS/MS
Parameters and corresponding hazardous substances
Hazardous substance CAS No. Parameter CAS No.
1,2,5,6,9,10-Hexabromocyclododecane 3194-55‑6 1,2,5,6,9,10-Hexabromocyclododecane 3194-55‑6
α‑HBCDD 134237-50‑6 α‑HBCDD 134237-50‑6
β‑HBCDD 134237-51‑7 β‑HBCDD 134237-51‑7
γ-HBCDD 134237-52‑8 γ-HBCDD 134237-52‑8
Reliability data
α-HBCDD
Standard deviation (rel.) sw  = 21.3%, 13.1% or 10.5%
Prognostic range u = 48.2%, 29.6% or 23.8%
Within-day precision:
at a spiked concentration of 0.1 µg, 1.0 µg or 10.0 µg α‑HBCDD per litre
plasma and where n = 10 determinations
Standard deviation (rel.) sw  = 18.2%, 11.7% or 6.5%
Prognostic range u = 41.2%, 26.5% or 14.7%
Day-to-day precision:
at a spiked concentration of 0.1 µg, 1.0 µg or 10.0 µg α‑HBCDD per litre
plasma and where n = 10 determinations
Recovery rate (rel.) r = 95%, 103% or 95%Accuracy:
at a spiked concentration of 0.1 µg, 1.0 µg or 10.0 µg α‑HBCDD per litre
plasma and where n = 10 determinations
Detection limit: 0.03 µg α‑HBCDD per litre plasma
Quantitation limit: 0.1 µg α‑HBCDD per litre plasma
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β-HBCDD
Standard deviation (rel.) sw  = 16.3%, 9.1% or 6.5%
Prognostic range u = 37.6%, 20.6% or 14.7%
Within-day precision:
at a spiked concentration of 0.1 µg, 1.0 µg or 10.0 µg β‑HBCDD per litre
plasma and where n = 9 or 10 determinations
Standard deviation (rel.) sw  = 14.0%, 10.4% or 10.9%
Prognostic range u = 31.7%, 23.5% or 24.7%
Day-to-day precision:
at a spiked concentration of 0.1 µg, 1.0 µg or 10.0 µg β‑HBCDD per litre
plasma and where n = 10 determinations
Recovery rate (rel.) r = 104%, 98% or 97%Accuracy:
at a spiked concentration of 0.1 µg, 1.0 µg or 10.0 µg β‑HBCDD per litre
plasma and where n = 10 determinations
Detection limit: 0.03 µg β‑HBCDD per litre plasma
Quantitation limit: 0.1 µg β‑HBCDD per litre plasma
γ-HBCDD
Standard deviation (rel.) sw  = 14.0%, 8.7% or 7.2%
Prognostic range u = 31.7%, 19.7% or 16.3%
Within-day precision:
at a spiked concentration of 0.1 µg, 1.0 µg or 10.0 µg γ -HBCDD per litre
plasma and where n = 10 determinations
Standard deviation (rel.) sw  = 17.6%, 13.5% or 6.9%
Prognostic range u = 39.8%, 30.5% or 15.6%
Day-to-day precision:
at a spiked concentration of 0.1 µg, 1.0 µg or 10.0 µg γ -HBCDD per litre
plasma and where n = 10 determinations
Recovery rate (rel.) r  = 95%, 98% or 108%Accuracy:
at a spiked concentration of 0.1 µg, 1.0 µg or 10.0 µg γ -HBCDD per litre
plasma and where n = 10 determinations
Detection limit: 0.03 µg γ -HBCDD per litre plasma
Quantitation limit: 0.1 µg γ -HBCDD per litre plasma
2 General information on HBCDD
1,2,5,6,9,10-Hexabromocyclododecane (HBCDD) is a white odourless powder with a density of 2.24–2.38 g/cm3
and a melting point of 180–185 ℃. HBCDD is a highly lipophilic compound with a logKOW of 5.625 and decom-
poses at temperatures above 190 ℃. Accordingly, its water solubility, which was determined to be approximately
66 µg/l for the technical mixture, is rather poor (NICNAS 2012). It is industrially produced by bromination of
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1,5,9-cyclododecatriene. Technical-grade HBCDDmainly consists of the three diastereomers α‑HBCDD, β‑HBCDD
and γ -HBCDD, with each of them existing as pairs of enantiomers. In total, up to 16 stereoisomeric forms are pos-
sible (Arsenault et al. 2007 a, b). Depending on the batch, the technical HBCDD mixture consists of approximately
72–90% γ -HBCDD, 9–13% α‑HBCDD and < 0.5–12% β‑HBCDD (EFSA 2011). The stereoisomers δ-HBCDD and
ε-HBCDD, which are also formed during production, are not considered as analytes in the present method due
to their low average concentration of < 1% (Heeb et al. 2005, 2008).
Figure 1 shows the chemical structures of α‑HBCDD, β‑HBCDD and γ -HBCDD.
Fig. 1 Structures of the stereoisomers α-HBCDD, β-HBCDD and γ-HBCDD
The production and use of HBCDD is prohibited within the EU since 2016. HBCDD was marketed under various
trade names (i.e. Pyroguard®, Pyrovatex®, Saytex®, Myflam®, HBCD or Nicca-Fi-None®) and was primarily used as
a flame retardant in expanded or extruded polystyrene. For example, HBCDD was used in polystyrene panels for
thermal insulation. It was also used in plastic packaging, in plastic housings for electrical and electronic appliances
and in electro-technical components such as cables. Additionally, HBCDD was also used to a lesser extent as textile
coating additive and to manufacture upholstered furniture, mattresses or car seats (ECHA 2010 a). Its use as a flame
retardant is the result of its ability to reduce flammability and to slow down the fire spread. As an additive, HBCDD
is not chemically bound to the polymer matrix but is only incorporated in the plastic matrix (NICNAS 2012).
In 2008, the European Union identified HBCDD as a substance of very high concern (SVHC) and as a persistent,
bioaccumulative and toxic substance (PBT substance). Consequently, in 2011 it was listed in Annex XIV of the
REACH Regulation (substances subject to authorisation) (ECHA 2010 a; EU 2011 a). In May 2013, HBCDD was
included in Annex A of the Stockholm POP Convention on Persistent Organic Pollutants, which was subsequently
approved by a respective UN conference (UN 2017). As of 23 March 2016, the production of HBCDD on its own or in
preparations has been prohibited (EU 2016). As of 2006, approximately 12 000 tons of HBCDD were used annually
in Europe (IOM 2008).
HBCDD may be released from products, to which it was added, by leaching or abrasion during their entire life
cycle and can thus be found in air, water or dust (Abdallah and Harrad 2009). This may be due to products from the
direct living environment as well as to improperly disposed waste. As HBCDD belongs to the persistent substances
it may remain in the environment for a long time. Tests indicate a half-life in soil between 119 and 210 days, with
α‑HBCDD showing the longest half-life of all HBCDD stereoisomers. Also the elimination of HBCDD from the
body appears to be rather slow with an elimination half-life being in the order of weeks to months (ECHA 2010 a).
Airborne HBCDD has even been detected in the Arctic region. It is also found worldwide in soil, sediment and
water (NICNAS 2012). Due to its high lipophilicity, HBCDD tends to accumulate in the fatty tissue of organisms.
The highest concentrations were detected in fish and eggs (EFSA 2011; Janák et al. 2005). Thus, humans may still
incorporate HBCDD through various routes of exposure. HBCDD has also been detected in human breast milk, so
that infants are as well potentially exposed (Abdallah and Harrad 2011; Eljarrat et al. 2009; Kakimoto et al. 2008;
Weiss et al. 2006). Studies on human metabolism are not yet available. However, Geyer et al. (2004) calculated the
half-life for humans to be 64 days, using two different approaches.
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HBCDD has not been evaluated by the Commission yet. A comprehensive presentation of relevant toxicological
studies can be found in the risk assessment report of the EU (2011 b), in the background documents of the European
Chemicals Agency (ECHA 2010 a, b) as well as in the document of the Australian National Industrial Chemicals
Notification and Assessment Scheme (NICNAS 2012). Reference or limit values in biological material derived by
the Commission are not available, but the Human Biomonitoring Commission (HBM Commission) of the German
Federal Environment Agency derived a HBM I value of 1.6 µg HBCDD per litre plasma (UBA 2015).
This analytical method allows the selective determination of HBCDD levels in human plasma. To determine possible
background exposure, 48 individual plasma samples from individuals not occupationally exposed to HBCDD were
analysed. The data obtained with this method are presented in Table 1.
Tab. 1 Background levels of α-, β- and γ-HBCDD in plasma (n = 48)
Analyte Median [µg/l] Mean [µg/l] Number > LOD Number < LOQ
α‑HBCDD < 0.1 < 0.1 3 (0.03 µg/l, 0.04 µg/l, 0.08 µg/l) 48
β‑HBCDD < 0.1 < 0.1 0 48
γ-HBCDD < 0.1 < 0.1 0 48
3 General principles
This analytical method enables the selective detection of the flame retardant HCBDD in plasma, with α‑HBCDD,
β‑HBCDD and γ ‑HBCDD being the three main stereoisomers of technical HBCDD. The analytes are extracted from
plasma after adding the corresponding 13C‑labelled internal standards. After precipitation of the plasma proteins
and solid phase extraction using Florisil® cartridges, the analytes are separated from accompanying components
by liquid chromatography and analysed using tandem mass spectrometry. Calibration standards are prepared in
plasma and processed in the same way as the samples to be analysed.
4 Equipment, chemicals and solutions
4.1 Equipment
• LC-MS/MS system:Waters Alliance LC 2695 coupled with a WatersQuattro Ultima tandemmass spectrometer
(Waters GmbH, Eschborn, Germany)
• LC column: Waters Atlantis T3 3 µm, 3.0 × 50 mm (Waters GmbH, Eschborn, Germany, No. 186003721)
• Laboratory shaker (e.g. IKA-Werke GmbH & Co. KG, Staufen, Germany)
• Pasteur pipettes (e.g. transfer pipettes made of polyethylene, Sarstedt AG & Co. KG, Nümbrecht, Germany)
• Analytical balance (e.g. Sartorius AG, Göttingen, Germany)
• Blood collection set with EDTA (e.g. Vacutainer®, Becton Dickinson GmbH, Heidelberg, Germany, No. 367864)
• Various volumetric flasks (e.g. Brand GmbH & Co. KG, Wertheim, Germany)
• 12 ml screw top vials with Teflon-coated screw caps (e.g. SCHOTT AG, Mainz, Germany)
• Variably adjustable pipettes (e.g. Eppendorf AG, Hamburg, Germany)
• Multipette® (e.g. Eppendorf AG, Hamburg, Germany)
The MAK Collection for Occupational Health and Safety 2020, Vol 5, No 3 5
Biomonitoring Methods – Hexabromocyclododecane in plasma
• Florisil® SPE cartridges 6 ml/1000 mg (MACHEREY-NAGELGmbH&Co. KG, Düren, Germany, No. 730082.250)
• 200 µl autosampler microvials with crimp caps (e.g. MACHEREY-NAGEL GmbH & Co. KG, Düren, Germany,
No. 702891/702025)
• Refrigerated centrifuge (e.g. Heraeus Deutschland GmbH & Co. KG, Hanau, Germany)
4.2 Chemicals
Unless otherwise specified, all chemicals must be at least p.a. grade.
• Acetonitrile, SupraSolv® (e.g. Merck KGaA, Darmstadt, Germany, No. 100665)
• Ultrapure water (e.g. Merck KGaA, Darmstadt, Germany, Milli-Q® water)
• Methanol, SupraSolv® (e.g. Merck KGaA, Darmstadt, Germany, No. 106011)
• Ethanol, SupraSolv® (e.g. Merck KGaA, Darmstadt, Germany, No. 102371)
• Dichloromethane, SupraSolv® (e.g. Merck KGaA, Darmstadt, Germany, No. 106054)
• n-Hexane, SupraSolv® (e.g. Merck KGaA, Darmstadt, Germany, No. 104371)
• iso-Octane, SupraSolv® (e.g. Merck KGaA, Darmstadt, Germany, No. 115440)
• Ammonium acetate, Emsure® (e.g. Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany, No. 1.01116)
• α‑HBCDD, 50 mg/l in toluene (e.g. Cambridge Isotope Laboratories Inc., Tewksbury, USA, No. ULM-4834‑1.2)
• α‑HBCDD-13C12, 50 mg/l in toluene (e.g. Cambridge Isotope Laboratories Inc., Tewksbury, USA, No. CLM-
7922‑0.5)
• β‑HBCDD, 50 mg/l in toluene (e.g. Cambridge Isotope Laboratories Inc., Tewksbury, USA, No. ULM-5835‑1.2)
• β‑HBCDD-13C12, 50 mg/l in toluene (e.g. Cambridge Isotope Laboratories Inc., Tewksbury, USA, No. CLM-
7923‑1.2)
• γ -HBCDD, 50 mg/l in toluene (e.g. Cambridge Isotope Laboratories Inc., Tewksbury, USA, No. ULM-4836‑1.2)
• γ -HBCDD-13C12, 50 mg/l in toluene (e.g. Cambridge Isotope Laboratories Inc., Tewksbury, USA, No. CLM-
7924‑1.2)
4.3 Solutions
• Aqueous ammonium acetate solution (5 mmol/l)
Exactly 385 mg ammonium acetate are weighed into a 1000 ml volumetric flask and dissolved in ultrapure
water. The volumetric flask is then made up to the mark with ultrapure water.
The solution is stored at room temperature and is stable for at least one week under these conditions.
• Dichloromethane : n-hexane 2 : 8 (v : v)
100 ml dichloromethane are pipetted into a 500 ml volumetric flask. The volumetric flask is then made up to
the mark with n-hexane.
The solution is stored at room temperature and is stable for at least six months under these conditions.
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4.4 Internal standards (ISTD)
• ISTD spiking solution (1 mg/l)
200 µl of each stock solution (α‑HBCDD-13C12, β‑HBCDD-13C12 and γ -HBCDD-13C12) are pipetted into a 10 ml
volumetric flask. The flask is then made up to the mark with methanol.
The spiking solution of the internal standards is stored at 4 ℃ and is stable for at least 12 months under these
conditions.
4.5 Calibration standards
• Stock solution (1 mg/l)
200 µl each of the individual stock solutions (α‑HBCDD, β‑HBCDD and γ -HBCDD) are pipetted into a 10 ml
volumetric flask. The flask is then made up to the mark with methanol.
• Spiking solution 1 (0.1 mg/l)
1 ml of the stock solution is pipetted into a 10 ml volumetric flask. The flask is then made up to the mark with
methanol.
• Spiking solution 2 (0.01 mg/l)
100 µl of the stock solution are pipetted into a 10 ml volumetric flask. The flask is then made up to the mark
with methanol.
• Spiking solution 3 (0.001 mg/L)
100 µl of spiking solution 1 are pipetted into a 10 ml volumetric flask. The flask is then made up to the mark
with methanol.
The solutions are stored at 4 ℃ and are stable for at least 12 months under these conditions.
Calibration standards in a calibration range between 0.05 µg/l and 5 µg/l are prepared according to the pipetting
scheme shown in Table 2. Unspiked pooled plasma is included as a blank.
Tab. 2 Pipetting scheme for the preparation of calibration standards used to determine HBCDD in plasma




1 1000 – – 0
2  950 3 50 0.05
3  990 2 10 0.1
4  980 2 20 0.2
5  950 2 50 0.5
6  990 1 10 1.0
7  980 1 20 2.0
8  950 1 50 5.0
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5 Specimen collection and sample preparation
5.1 Specimen collection
After the puncture site has been disinfected, about 5 ml blood are taken from the arm vein of the person to be
examined using a blood collection set with anticoagulant additive (EDTAVacutainer®).The filled tube is then gently
inverted to ensure proper mixing of blood and anticoagulant. The blood sample is then centrifuged at 2200 × g for
ten minutes. The upper plasma phase is transferred into a sealable glass tube using a pipette.
The plasma can be stored in the refrigerator at 4 ℃ for one week or in the freezer at −20 ℃ for at least one year.
5.2 Sample preparation
1 ml of the plasma is pipetted into a screw top vial. Using a pipette, 5 µl of the ISTD spiking solution and 200 µl
ethanol are added to the sample, which is shaken briefly. 5 ml n-hexane are then added to the sample, the vial is
sealed and the sample is mixed thoroughly on the laboratory shaker for ten minutes. The sample is then centrifuged
at 2200 × g for ten minutes at 10 ℃.
The SPE cartridge is conditioned using 3 ml dichloromethane and subsequently 8 ml n-hexane.Then, the supernatant
of the centrifuged sample (hexane phase) is loaded onto the conditioned cartridge using a pipette. The hexane
passing through is discarded. Subsequently, the analytes are eluted with 5 ml of the solution of dichloromethane : 
n-hexane 2 : 8 (v/v) into a new vial. The eluate is evaporated to dryness with nitrogen (50 kPa at 35 ℃) and the
residue is resolved in 100 µl ammonium acetate solution. The sample is then transferred to a 200 µl micro-vial, the
vial is sealed and can then be used directly for analysis.
6 Operational parameters
Analysis was performed using a Waters Alliance HPLC system coupled with a Waters Quattro Ultima tandem mass
spectrometer.
6.1 High performance liquid chromatography
Analytical column: Waters Atlantis T3 3 µm, 3.0 × 50 mm
A: methanol








Gradient pump: Gradient program see Table 3
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Tab. 3 Gradient pump program
Time [min] Mobile phase A [Vol.-%] Mobile phase B [Vol.-%] Mobile phase C [Vol.-%]
 0 20 40 40
 1.5 20 20 60
 2.5 20 10 70
10 20 10 70
10.05 20  0 80
11 20  0 80
12 20 40 40
All other parameters have to be optimised in accordance with the manufacturer’s specifications.
6.2 Tandem mass spectrometry
Ionisation mode: negative electrospray ionisation (ESI−)
Source temperature: 120 ℃
Desolvation temperature: 300 ℃
Cone gas flow: 276 l/h
Desolvation gas flow 499 l/h
Collision: 30 eV
Multiplier: 650 V




Parameter-specific settings see Table 4
Tab. 4 Parameter-specific settings for the analytes and the internal standards
Ion trace [m/z]Analyte Retention time [min]
Precursor ion Product ion
α‑HBCDD 7.7 641 79
β‑HBCDD 7.9 641 79
γ-HBCDD 8.4 641 79
α‑HBCDD-13C12 7.7 653 79
β‑HBCDD-13C12 7.9 653 79
γ-HBCDD-13C12 8.4 653 79
The LC-MS/MS product ion spectra of HBCDD-13C12 and HBCDD are presented in Figure 2 and the isotope distribu-
tion (due to the contained bromine atoms) is shown in Figure 3. The MRM transitions correspond to the fragmenta-
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tion of the [M–H]− pseudomolecular ions to 79Br−. The mass 81 (corresponding to 81Br−) resulting from the isotope
distribution can be used to verify the results. A summation of 79Br− and 81Br− peak areas results in a more sensitive
determination of HBCDD.
Fig. 2 Product ion spectra of HBCDD-13C12 and HBCDD
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Fig. 3 Isotope distribution of HBCDD-13C12 and HBCDD
All settings of the ion source as well as the MRM parameters are instrument-specific and must be adjusted individu-
ally by the user. The parameters specified above are therefore intended as a rough guide only.
7 Analytical determination
20 µl of each of the samples prepared as described in Section 5 are injected into the LC-MS/MS system. Identification
of the individual analytes is based on the retention times and ion traces of each analyte (Table 4).The retention times
given in Table 4 are intended as a rough guide only. Users must ensure proper separation performance of the column
used which influences the resulting retention behaviour of the analytes. Figures 4 and 5 show chromatograms of
a native plasma sample and of a plasma sample spiked with 0.1 µg/l of each analyte.
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Fig. 4 Chromatogram of a native plasma sample
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Fig. 5 Chromatogram of a plasma sample spiked with 0.1 µg/l of each of the analytes
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8 Calibration
The calibration standards prepared as described in Section 4.5 are processed and analysed according to Section 5.2.
Calibration graphs are obtained by plotting the peak area ratios of the respective analyte and of the corresponding
13C‑labelled internal standard against the spiked analyte levels. The calibration graph is linear in the concentration
range from the detection limit to 100 µg/l. Usually, a calibration range up to 5 µg/l should be sufficient. As an
example, Figure 6 shows the calibration graphs for α‑HBCDD, β‑HBCDD and γ -HBCDD in plasma.
Fig. 6 Calibration graphs for the determination of α-HBCDD, β-HBCDD and γ-HBCDD in plasma
9 Calculation of the analytical results
The analyte concentrations in the plasma samples are calculated using the calibration functions of the respective
analytical run (Section 8). The determined peak areas of the individual HBCDD isomers are divided by the peak
areas of the corresponding internal standard. The quotients thus obtained are entered into the equation to give
the respective analyte concentration in µg/l. Any reagent blank values have to be subtracted from the analytical
results.
10 Standardisation and quality control
Quality control of the analytical results is carried out as stipulated in the guidelines of the Bundesärztekammer
(German Medical Association) and in a general chapter of the MAK-Collection for Occupational Health and Safety
(Bader et al. 2010; Bundesärztekammer 2014). For quality control, at least three plasma quality control samples with
known analyte concentrations are analysed within each analytical run. As control material is not commercially
available for the analytes, it must be prepared in the laboratory. To this end, pooled plasma from individuals not
occupationally exposed to HBCDD is used and spiked with 0.1 µg/l, 1.0 µg/l or 5 µg/l of each of α‑HBCDD, β‑HBCDD
and γ -HBCDD. Aliquots of these materials are stored at −20 ℃ and are included in each analytical run as quality
control samples. The nominal values and the tolerance ranges of the quality control materials are determined
in a pre-analytical period (one analysis of the control materials each on ten different days) (Bader et al. 2010).
Additionally, at least one reagent blank is included in each analytical run to identify potential interferences caused
by the reagents.
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11 Evaluation of the method
The reliability of the method was verified by comprehensive validation as well as by implementation and validation
of the method in a second, independent laboratory.
11.1 Precision
Within-day precision was determined using pooled plasma from individuals not occupationally exposed to HBCDD.
Ten plasma samples each were spiked with analyte concentrations of 0.1 µg/l, 1.0 µg/l and 10.0 µg/l of each of the
analytes. These samples were processed (Section 5.2) and analysed (Section 6) as described. The obtained precision
data are presented in Table 5.







Prognostic range u [%]
 0.1  0.097 21.3 48.2
 1.0  1.03 13.1 29.6
α‑HBCDD
10.0 10.8 10.5 23.8
 0.1a)  0.099 16.3 37.6
 1.0  1.01  9.1 20.6
β‑HBCDD
10.0  9.86  6.5 14.7
 0.1  0.102 14.0 31.7
 1.0  0.85  8.7 19.7
γ-HBCDD
10.0  8.96  7.2 16.3
a) Outlier eliminated, n = 9
Day-to-day precision was also determined using pooled plasma from individuals not occupationally exposed to
HBCDD. Two plasma samples eachwith analyte concentrations of 0.1 µg/l, 1.0 µg/l and 10.0 µg/l eachwere processed
and analysed on five different days. The precision data thus obtained are presented in Table 6.







Prognostic range u [%]
 0.1  0.095 18.2 41.2
 1.0  1.03 11.7 26.5
α‑HBCDD
10.0  9.77  6.5 14.7
 0.1  0.104 14.0 31.7
 1.0  0.98 10.4 23.5
β‑HBCDD
10.0  9.65 10.9 24.7
 0.1  0.095 17.6 39.8
 1.0  0.98 13.5 30.5
γ-HBCDD
10.0 10.8  6.9 15.6
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11.2 Accuracy
The accuracy of the method was determined on the basis of the within-day precision data and the day-to-day
precision data. The relative recovery rates thus obtained are presented in Tables 7 and 8.
Tab. 7 Mean relative recovery rates for the determination of α-, β- and γ-HBCDD in plasma, derived from the within-day precision
data (n = 10)














Tab. 8 Mean relative recovery rates for the determination of α-, β- and γ-HBCDD in plasma, derived from the day-to-day precision
data (n = 10)













11.3 Limits of detection and limits of quantitation
The detection limits and quantitation limits were determined on the basis of a signal-to-noise ratio of 3 : 1 for the
detection limits and of 9 : 1 for the quantitation limits. The values calculated for the three analytes in plasma are
shown in Table 9.
Tab. 9 Limits of detection and limits of quantitation for the determination of α-, β- and γ-HBCDD in plasma (n = 3)
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11.4 Sources of error
Various LC columns were tested for their separation performance during method development, but only
Nucleodur C18 ISIS (MACHEREY-NAGEL GmbH & Co. KG, Düren, Germany, No. 760413.20), XSelect HSS C18
(Waters GmbH, Eschborn, Germany, No. 186006138) and the Atlantis T3 (Waters GmbH, Eschborn, Germany,
No. 186003721) were able to achieve stable separation of all three isomers over a longer period of time. The
separation of the three HBCDD stereoisomers was not the only selection criterion though. It was observed that
a large number of LC columns tested rapidly decreased in separation performance and inertness. This phenomenon
was also observed when pure standard solutions were injected, so that the possible accompanying matrix could be
ruled out as the cause. For the analyses described herein, two columns, XSelect and Atlantis T3 attained narrow
peaks and thus good peak separation of α‑HBCDD and β‑HBCDD.
The SPE purification technique using Florisil® cartridges is well known from PCB analysis and also proved to
be very effective for the determination of HBCDD isomers, as it enabled a selective removal of plasma lipids.
A concentration factor of 10 was achieved by evaporating the sample to dryness and taking up the residue in 100 µl
of ammonium acetate solution.
The analytical determination by LC-MS/MS showed that the mass fragmentm/z 79 had a higher intensity compared
to m/z 81. Quantification via m/z 79 and verification via m/z 81 resulted in a detection limit of 0.1 µg/l when using
a sample volume of 2 ml plasma. Further optimisation steps, such as the increase of the cone gas flow rate and the
summation of the peak areas of m/z 79 and m/z 81, resulted in a distinctly lower detection limit of 0.03 µg/l and
a quantitation limit of 0.1 µg/l for each of the three isomers when using a plasma volume of only 1 ml.
The analytical results of this method are expressed in terms of volume (µg/l); however, it should be noted that with
regard to HBCDD, there is an international consensus that the analytical results should be expressed in relation to
the lipid content of the blood plasma (ng/g lipid).This is based on the phenomenon that highly lipophilic xenobiotics
are distributed in body fat and thus the concentration of xenobiotics in blood plasma (or blood serum) depends
directly on the lipid levels in this matrix (Phillips et al. 1989). The lipid level, in turn, is dependent on various
factors, including food intake in the hours before the blood samples are taken. It can vary within a relatively wide
range of 4.5 to 12.6 g lipid/l blood plasma in adults (ICRP 1975).
During external verification, carry-over effects were observed after injection of samples with high analyte levels.
To avoid these, it is recommended to inject water after the injection of highly concentrated samples.
12 Discussion of the method
It is a special challenge to quantify HBCDD in biological material. Optimised instrument parameters and an effective
sample clean-up are required for the analytical determination of the HBCDD stereoisomers in the given detection
range (Covaci et al. 2007; Dodder et al. 2006; Marvin et al. 2007; Thomsen et al. 2008).
This analytical method allows the selective and robust quantification of α‑, β‑ and γ -HBCDD in plasma. The use of
only one millilitre of plasma and the quantitation limit of 0.1 µg/l enables the monitoring of occupational exposure
(Thomsen et al. 2007) as well as the monitoring of environmental HBCDD exposure, provided that the subjects
examined are exposed to specific sources of increased environmental HBCDD exposure (Li et al. 2014; Thomsen
et al. 2008). However, the general determination of the background exposure of the general population with this
method is not possible (see Table 1). For that purpose, other analytical methods with a higher sensitivity should be
used. However, not all of these methods enable a determination of individual HBCDD isomers (Bjermo et al. 2017;
Kalantzi et al. 2011; Li et al. 2014; Rawn et al. 2014; Roosens et al. 2009; Tang 2010; Thomsen et al. 2007, 2008; Weiss
et al. 2004, 2006).
The use of 13C‑labelled internal standards with similar fragmentation patterns is well suited to compensate for
various analytical deviations. This was confirmed by the overall very acceptable precision data, as the somewhat
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elevated relative standard deviations in the range between 14.0% and 21.3% were entirely due to the recovery tests
performed at the quantitation limit of the present method (0.1 µg/l).
In order to obtain an overview of possible background exposures, plasma samples from 48 individuals not occupa-
tionally exposed to HBCDDwere analysed. No analyte concentrations above the determined limit of quantitation of
0.1 µg/l could be quantified in any of the samples. In three samples, α-HBCDD levels above the LOD were detected,
i.e. 0.03 µg/l, 0.04 µg/l and 0.08 µg/l (see Table 1).
During external verification, detection limits of 0.02 µg/l (α‑HBCDD and β‑HBCDD) and 0.01 µg/l (γ -HBCDD) as
well as quantitation limits of 0.05 µg/l (α‑HBCDD and β‑HBCDD) and 0.03 µg/l (γ -HBCDD) were determined using
a different LC-MS/MS system: AB Sciex QTrap 5500 (AB Sciex Germany GmbH, Darmstadt, Germany). Despite the
improved quantitation limits, HBCDD could not be quantified in any of 30 plasma samples from the general popu-
lation. This was further confirmed by a later transfer of the method to a more sensitive LC-MS/MS system (Waters
Xevo TQ‑S with Waters Acquity UPLC H‑Class, column: Acquity UPLC HSS T3, 1.8 µm, 100 Å, 2.1 mm × 100 mm
(Waters GmbH, Eschborn, Germany)). In particular, significantly better relative standard deviations for within-day
precision (2–9%, instead of 7–21%) and day-to-day precision (2–12%, instead of 7–18%) could be achieved with this
instrument, with consistently good recovery rates. The accuracy of this enhanced method has been confirmed by
successful participation in interlaboratory tests within the HBM4EU project (Dvorakova et al. 2020; Lankova et al.
2018, 2019 a, b).
Instruments used LC-MS/MS system: Waters Alliance LC 2695 coupled with Waters Quattro Ultima Tandem MS.
LC column: Waters Atlantis T3 3 µm, 3.0 × 50 mm. Instrument software: MassLynx 4.1 (Waters GmbH, Eschborn,
Germany).
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